GLP1R and obesity due to melanocortin 4 receptor deficiency: GLP-1R agonists can effectively lower body weight in obese patients to levels not achieved before with anti-obesity therapies [11,53]; however, weight loss seems to plateau over time and with diminishing gains as dose is increased within tolerable ranges [11].